Roche Presents Several Abstracts for New Targeted Cancer Drugs at ASCO

Abstracts presented by Roche at ASCO's annual meeting showed Herceptin's efficacy in stomach cancer patients; demonstrated the treatment benefit of combining Herceptin with the cell-killing drug DM1 in metastatic breast cancer patients; and suggested the development of a new BRAF-targeting melanoma drug and companion diagnostic.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.